<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 12pt">UNITED STATES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>WASHINGTON,
D. C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 15%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 12pt">FORM 8-K</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CURRENT REPORT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Pursuant to Section 13 or 15(d) of the</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Securities Exchange Act Of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>February 2, 2012</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Date of Report (Date of earliest event reported)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 70%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CADISTA HOLDINGS INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact Name of Registrant as Specified in Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 70%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;<B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; layout-grid-mode: line; font-weight: bold; text-align: center">State of Delaware</TD>
    <TD STYLE="width: 1%; layout-grid-mode: line; font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 34%; layout-grid-mode: line; font-weight: bold; text-align: center"><B>000-54421</B></TD>
    <TD STYLE="width: 1%; layout-grid-mode: line; font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; layout-grid-mode: line; font-weight: bold; text-align: center">31-1259887</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; layout-grid-mode: line">(State of Other Jurisdiction</TD>
    <TD STYLE="text-align: center; layout-grid-mode: line">&nbsp;</TD>
    <TD STYLE="text-align: center; layout-grid-mode: line">(Commission File Number)</TD>
    <TD STYLE="text-align: center; layout-grid-mode: line">&nbsp;</TD>
    <TD STYLE="text-align: center; layout-grid-mode: line">&nbsp;(I.R.S. Employer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; layout-grid-mode: line">of Incorporation)</TD>
    <TD STYLE="text-align: center; layout-grid-mode: line">&nbsp;</TD>
    <TD STYLE="text-align: center; layout-grid-mode: line">&nbsp;</TD>
    <TD STYLE="text-align: center; layout-grid-mode: line">&nbsp;</TD>
    <TD STYLE="text-align: center; layout-grid-mode: line">Identification Number)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">207 Kiley Drive</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Salisbury, MD 21801</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Address of principal executive offices)
(Zip Code)</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>(410) 912-3700</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">(Registrant&rsquo;s telephone number, including
area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; font-family: Wingdings; layout-grid-mode: line; text-align: center">&uml;</TD>
    <TD STYLE="width: 94%; layout-grid-mode: line; text-align: left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Wingdings; layout-grid-mode: line; text-align: center">&uml;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: left">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Wingdings; layout-grid-mode: line; text-align: center">&uml;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: left">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-2(b))</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Wingdings; layout-grid-mode: line; text-align: center">&uml;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: left">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid; text-align: center"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; text-align: center"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0"><B>Item 1.01 Entry into Material Definitive Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">On February 2, 2012, our wholly-owned subsidiary, Jubilant
Cadista Pharmaceuticals Inc. (&ldquo;Cadista Pharmaceuticals&rdquo;) entered into a credit facility agreement (the &ldquo;ICICI
Bank Credit Facility Agreement&rdquo;) with ICICI Bank Limited, New York Branch (&ldquo;ICICI Bank NY&rdquo;), providing for borrowings
and other credit accommodations of up to $8,500,000 (the &ldquo;Maximum Amount&rdquo;). On the same date, Cadista Pharmaceuticals
entered into an amendment to its credit agreement with State Bank of India, New York Branch (&ldquo;SBNY&rdquo;), to, among other
things, reflect that SBNY&rsquo;s security interest will rank pari passu in those items of collateral in which both ICICI Bank
NY and SBNY will have a security interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0"><U>The ICICI Bank Facility Agreement</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">The ICICI Bank Credit Facility Agreement contemplates
that ICICI Bank NY may extend the following loans and credit accommodations to Cadista Pharmaceuticals to be used, depending upon
the facility, for purchasing raw materials or capital equipment for its manufacturing process or working capital purposes: revolving
loans (&ldquo;ICICI Bank Revolving Loans;&rdquo; and the credit facility pursuant to which such loans are issued, the &ldquo;ICICI
Bank Revolving Loan Credit Facility&rdquo;); the issuance of letters of credit for Cadista Pharmaceuticals account (the &ldquo;ICICI
Bank Letters of Credit Facility&rdquo;); and a facility enabling Cadista Pharmaceuticals to discount and receive payment for certain
customer invoices (the &ldquo;ICICI Bank Bill Discounting Facility&rdquo;). The ICICI Bank Credit Facility Agreement has a term
that expires on the first anniversary of the agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">ICICI Bank Revolving Loans are extended and required
to be repaid so that the ICICI Bank Revolving Loans, together with the amounts drawn under or due and owing under the ICICI Banks
Letters of Credit Facility and the ICICI Bank Bill Discounting Facility, do not exceed a specified percentage of the sum of (i)
accounts receivable satisfying certain criteria and subject to certain adjustments and (ii) inventory created and used in Cadista
Pharmaceutical&rsquo;s ordinary course of business. The ICICI Bank Letters of Credit Facility provides for the issuance of letters
of credit, with durations ending prior to the first anniversary of the ICICI Bank Credit Facility Agreement. The ICICI Bank Bill
Discounting Facility provides for advances, based upon invoices issued to specified customers, subject to a sublimit per customer
of $4,000,000 in the aggregate. The aggregate amount of loans and credit accommodations that are provided under the three facilities
is capped at the Maximum Amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">If not otherwise payable before, all amounts under all
three facilities are due on the expiration date of the ICICI Bank Credit Facility Agreement. The ICICI Bank Revolving Loans may
be payable earlier on demand. Cadista Pharmaceuticals is required to promptly reimburse ICICI Bank NY for all amounts drawn under
the letters of credit, which reimbursement may be in the form of an ICICI Bank Revolving Loan to the extent Cadista Pharmaceuticals
is able to borrow such amount under the ICICI Bank Revolving Loan Credit Facility at that time. Advances under the ICICI Bank NY&rsquo;s
Bill Discounting Facility are payable 120 days after the advance (or if earlier, upon the demand for repayment of the ICICI Bank
Revolving Loans). Interest on outstanding amounts of ICICI Bank Revolving
Loans accrues at a rate equal to the three month LIBOR rate plus three and three-fourths percent (3.75%) per annum. Interest on
the outstanding amount of advances under the ICICI Bank Bill Discounting Facility accrues at a rate equal to the three month LIBOR
rate plus three (3%) per annum. Interest on both facilities is payable monthly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid; text-align: center"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; text-align: center"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">The ICICI Bank Credit Facility
Agreement requires Cadista Pharmaceuticals to maintain as of March 31 and September 30 of each fiscal year: (i) an asset coverage
ratio equal to the &ldquo;Bank&rsquo;s Pro Rata Share of Borrower&rsquo;s Assets&rdquo; (as defined in the ICICI Bank Credit Facility
Agreement) divided by the amounts then outstanding under the ICICI Bank Credit Facility Agreement (and the other credit documents
executed in connection therewith) of not less than 1.40; and (ii) a ratio of its outstanding long-term debt, plus outstanding
amounts of working capital or short term debt of Cadista Pharmaceuticals, divided by &ldquo;EBITDA&rdquo; (i.e. earnings before
interest, taxes, depreciation, and amortization) of no more than 3.00. For purposes of the ICICI Bank NY Credit Facility Agreement:
the &ldquo;Bank&rsquo;s Pro Rata Share of Borrower&rsquo;s Assets&rdquo; is equal to the product of: (x) 8.5 divided by 15 (which
is the proportion that the Maximum Amount bears to the combined maximum amounts that may be borrowed or credit accommodations
provided under the SBNY Revolver and the ICICI Bank Credit Facility Agreement), and (y) Cadista Pharmaceutical&rsquo;s current
assets. If Cadista Pharmaceutical&rsquo;s financial statements reflect negative EBITDA for any six (6) month period, it may be
required to fund a reserve account with ICICI Bank in an amount equal to six (6) months of interest payable on the principal amount
outstanding under the ICICI Bank Credit Facility Agreement for the prior six (6) month period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">The ICICI Bank Credit
Facility Agreement contains various covenants, including: covenants restricting changes in control (including that Jubilant
Life Sciences Limited maintain at least a 51% equity interest in us); upon ICICI Bank NY&rsquo;s request, requiring Cadista
Pharmaceuticals to obtain a credit rating with respect to itself or the loan transactions; covenants restricting the
repayment of affiliate indebtedness; and other restrictions similar to those contained in Cadista Pharmaceuticals&rsquo;
credit agreement with State Bank of India, New York Branch (&ldquo;SBNY&rdquo;). All indebtedness of Cadista Pharmaceuticals
to us is subordinated to Cadista Pharmaceutical&rsquo;s obligations to ICICI Bank NY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">The ICICI Bank NY Credit Facility is secured by Cadista
Pharmaceutical&rsquo;s goods, inventory, accounts receivable, contract rights and current assets. ICICI Bank NY&rsquo;s security
interest ranks pari passu with the security interest of SBNY in the same assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0"><U>The Amendment to the
Credit Agreement with SBNY</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">The amendment to
Cadista Pharmaceuticals&rsquo; credit agreement with SBNY, in addition to effectuating modifications to reflect that
SBNY&rsquo;s security interest will rank pari passu in those items of collateral in which both ICICI Bank NY and SBNY will
have a security interest, effectuated the following changes: (i) the expiration date of the revolving credit facility was
extended from March 21, 2012 to November 18, 2012; (ii) a $1,000,000 sub-limit for the issuance of letters of credit was
established under the revolving credit facility; and (iii) requiring Cadista Pharmaceuticals to obtain a rating by a
reputable credit agency no later than September 30, 2012, failing which Cadista Pharmaceuticals will be required to pay
additional interest of 0.5% on the total commitment until it obtains such a rating.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid; text-align: center"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; text-align: center"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0"><B>Item 2.03&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Creation
of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">The information in Item 1.01, which describes the material
terms of the ICICI Bank Credit Facility Agreement, and documents related to such agreement, is incorporated into this Item 2.03
by this reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0"><B>Item 9.01 Financial Statements and Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 12%; border-bottom: windowtext 1pt solid; layout-grid-mode: line; font-weight: bold; text-align: center">Exhibit Number</TD>
    <TD STYLE="width: 2%; layout-grid-mode: line; font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 86%; border-bottom: windowtext 1pt solid; layout-grid-mode: line; font-weight: bold; text-align: center">Description</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line; font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line; text-align: center">10.1</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: left">Credit Facility Agreement, dated, February 2, 2012, among Jubilant Cadista Pharmaceuticals, Inc. (&ldquo;Cadista Pharmaceuticals&rdquo;), and ICICI Bank Limited, New York Branch (&ldquo;ICICI Bank NY&rdquo;)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line; text-align: center">10.2</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: left">Form of Promissory Note of Cadista Pharmaceuticals made to ICICI Bank NY, dated February 2, 2012</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line; text-align: center">10.3</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: left">Security Agreement, dated February 2, 2012, between Cadista Pharmaceuticals and ICICI Bank NY</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line; text-align: center">10.4</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: left">Subordination Agreement, dated February 2, 2012, between Cadista Holdings Inc. (&ldquo;CHI&rdquo;) and ICICI Bank NY</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line; text-align: center">10.5</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: left">Non-Disposal Undertaking, dated February 2, 2012, executed by CHI and Cadista Pharmaceuticals, for the benefit of ICICI Bank NY</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line; text-align: center">10.6</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: left">Intercreditor Agreement, dated February 2, 2012, among ICICI Bank NY, State Bank of India, New York Branch, Cadista Pharmaceuticals, and CHI</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line; text-align: center">10.7</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: left">Undertaking, dated February 2, 2012, by Jubilant Life Sciences Limited, for the benefit of ICICI Bank NY, acknowledged and agreed to by Cadista Pharmaceuticals and CHI</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%; layout-grid-mode: line; text-align: center">10.8</TD>
    <TD STYLE="width: 2%; layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: left; width: 86%">Second Amendment to Credit Modification Agreement, dated February 2, 2012, among State Bank of India, New York Branch (&ldquo;SBNY&rdquo;), Cadista Pharmaceuticals, and CHI</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line; text-align: center">10.9</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: left">Amendment to Security Agreement, dated February 2, 2012, between SBNY and Cadista Pharmaceuticals</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid; text-align: center"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; text-align: center"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line; font-weight: bold; text-align: center">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="layout-grid-mode: line; font-weight: bold; text-align: left">CADISTA HOLDINGS INC.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 4%; layout-grid-mode: line; text-align: left">By:</TD>
    <TD STYLE="width: 27%; layout-grid-mode: line; text-decoration: none; text-align: left; border-bottom: Black 1pt solid">/s/ Kamal Mandan</TD>
    <TD STYLE="width: 19%; layout-grid-mode: line; text-decoration: none; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="layout-grid-mode: line; text-align: left">Kamal Mandan</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="layout-grid-mode: line; text-align: left">Chief Financial Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">Date:&nbsp;&nbsp;&nbsp;February 7, 2012</P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid; text-align: center"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; text-align: center"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 12%; border-bottom: windowtext 1pt solid; layout-grid-mode: line; font-weight: bold; text-align: center">Exhibit Number</TD>
    <TD STYLE="width: 2%; layout-grid-mode: line; font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 86%; border-bottom: windowtext 1pt solid; layout-grid-mode: line; font-weight: bold; text-align: center">Description</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line; font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line; text-align: center">10.1</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: left">Credit Facility Agreement, dated, February 2, 2012, among Jubilant Cadista Pharmaceuticals, Inc. (&ldquo;Cadista Pharmaceuticals&rdquo;), and ICICI Bank Limited, New York Branch (&ldquo;ICICI Bank NY&rdquo;)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line; text-align: center">10.2</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: left">Form of Promissory Note of Cadista Pharmaceuticals made to ICICI Bank NY, dated February 2, 2012</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line; text-align: center">10.3</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: left">Security Agreement, dated February 2, 2012, between Cadista Pharmaceuticals and ICICI Bank NY</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line; text-align: center">10.4</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: left">Subordination Agreement, dated February 2, 2012, between Cadista Holdings Inc. (&ldquo;CHI&rdquo;) and ICICI Bank NY</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line; text-align: center">10.5</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: left">Non-Disposal Undertaking, dated February 2, 2012, executed by CHI and Cadista Pharmaceuticals, for the benefit of ICICI Bank NY</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line; text-align: center">10.6</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: left">Intercreditor Agreement, dated February 2, 2012, among ICICI Bank NY, State Bank of India, New York Branch, Cadista Pharmaceuticals, and CHI</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line; text-align: center">10.7</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: left">Undertaking, dated February 2, 2012, by Jubilant Life Sciences Limited, for the benefit of ICICI Bank NY, acknowledged and agreed to by Cadista Pharmaceuticals and CHI</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line; text-align: center">10.8</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: left">Second Amendment to Credit Modification Agreement, dated February 2, 2012, among State Bank of India, New York Branch (&ldquo;SBNY&rdquo;), Cadista Pharmaceuticals, and CHI.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line; text-align: center">10.9</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: left">Amendment to Security Agreement, dated February 2, 2012, between SBNY and Cadista Pharmaceuticals</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>



<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "v301502_8k.htm", "description": "CURRENT REPORT", "secsgml_size_bytes": 39465}]
{"company-data": {"conformed-name": "Cadista Holdings Inc.", "cik": "0001521762", "assigned-sic": "2834", "irs-number": "311259887", "state-of-incorporation": "DE", "fiscal-year-end": "0331"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-54421", "film-number": "12579372"}, "business-address": {"street1": "207 KILEY DRIVE", "city": "SALISBURY", "state": "MD", "zip": "21801", "phone": "410-912-3700"}, "mail-address": {"street1": "207 KILEY DRIVE", "city": "SALISBURY", "state": "MD", "zip": "21801"}}
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D. C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act Of 1934
February 2, 2012
Date of Report (Date of earliest event reported)
CADISTA HOLDINGS INC.
(Exact Name of Registrant as Specified in Charter)
State of Delaware
000-54421
31-1259887
(State of Other Jurisdiction
(Commission File Number)
(I.R.S. Employer
of Incorporation)
Identification Number)
207 Kiley Drive
Salisbury, MD 21801
(Address of principal executive offices)
(Zip Code)
(410) 912-3700
(Registrant's telephone number, including
area code)
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))
Item 1.01 Entry into Material Definitive Agreement
On February 2, 2012, our wholly-owned subsidiary, Jubilant
Cadista Pharmaceuticals Inc. ("Cadista Pharmaceuticals") entered into a credit facility agreement (the "ICICI
Bank Credit Facility Agreement") with ICICI Bank Limited, New York Branch ("ICICI Bank NY"), providing for borrowings
and other credit accommodations of up to $8,500,000 (the "Maximum Amount"). On the same date, Cadista Pharmaceuticals
entered into an amendment to its credit agreement with State Bank of India, New York Branch ("SBNY"), to, among other
things, reflect that SBNY's security interest will rank pari passu in those items of collateral in which both ICICI Bank
NY and SBNY will have a security interest.
The ICICI Bank Facility Agreement
The ICICI Bank Credit Facility Agreement contemplates
that ICICI Bank NY may extend the following loans and credit accommodations to Cadista Pharmaceuticals to be used, depending upon
the facility, for purchasing raw materials or capital equipment for its manufacturing process or working capital purposes: revolving
loans ("ICICI Bank Revolving Loans;" and the credit facility pursuant to which such loans are issued, the "ICICI
Bank Revolving Loan Credit Facility"); the issuance of letters of credit for Cadista Pharmaceuticals account (the "ICICI
Bank Letters of Credit Facility"); and a facility enabling Cadista Pharmaceuticals to discount and receive payment for certain
customer invoices (the "ICICI Bank Bill Discounting Facility"). The ICICI Bank Credit Facility Agreement has a term
that expires on the first anniversary of the agreement.
ICICI Bank Revolving Loans are extended and required
to be repaid so that the ICICI Bank Revolving Loans, together with the amounts drawn under or due and owing under the ICICI Banks
Letters of Credit Facility and the ICICI Bank Bill Discounting Facility, do not exceed a specified percentage of the sum of (i)
accounts receivable satisfying certain criteria and subject to certain adjustments and (ii) inventory created and used in Cadista
Pharmaceutical's ordinary course of business. The ICICI Bank Letters of Credit Facility provides for the issuance of letters
of credit, with durations ending prior to the first anniversary of the ICICI Bank Credit Facility Agreement. The ICICI Bank Bill
Discounting Facility provides for advances, based upon invoices issued to specified customers, subject to a sublimit per customer
of $4,000,000 in the aggregate. The aggregate amount of loans and credit accommodations that are provided under the three facilities
is capped at the Maximum Amount.
If not otherwise payable before, all amounts under all
three facilities are due on the expiration date of the ICICI Bank Credit Facility Agreement. The ICICI Bank Revolving Loans may
be payable earlier on demand. Cadista Pharmaceuticals is required to promptly reimburse ICICI Bank NY for all amounts drawn under
the letters of credit, which reimbursement may be in the form of an ICICI Bank Revolving Loan to the extent Cadista Pharmaceuticals
is able to borrow such amount under the ICICI Bank Revolving Loan Credit Facility at that time. Advances under the ICICI Bank NY's
Bill Discounting Facility are payable 120 days after the advance (or if earlier, upon the demand for repayment of the ICICI Bank
Revolving Loans). Interest on outstanding amounts of ICICI Bank Revolving
Loans accrues at a rate equal to the three month LIBOR rate plus three and three-fourths percent (3.75%) per annum. Interest on
the outstanding amount of advances under the ICICI Bank Bill Discounting Facility accrues at a rate equal to the three month LIBOR
rate plus three (3%) per annum. Interest on both facilities is payable monthly.
The ICICI Bank Credit Facility
Agreement requires Cadista Pharmaceuticals to maintain as of March 31 and September 30 of each fiscal year: (i) an asset coverage
ratio equal to the "Bank's Pro Rata Share of Borrower's Assets" (as defined in the ICICI Bank Credit Facility
Agreement) divided by the amounts then outstanding under the ICICI Bank Credit Facility Agreement (and the other credit documents
executed in connection therewith) of not less than 1.40; and (ii) a ratio of its outstanding long-term debt, plus outstanding
amounts of working capital or short term debt of Cadista Pharmaceuticals, divided by "EBITDA" (i.e. earnings before
interest, taxes, depreciation, and amortization) of no more than 3.00. For purposes of the ICICI Bank NY Credit Facility Agreement:
the "Bank's Pro Rata Share of Borrower's Assets" is equal to the product of: (x) 8.5 divided by 15 (which
is the proportion that the Maximum Amount bears to the combined maximum amounts that may be borrowed or credit accommodations
provided under the SBNY Revolver and the ICICI Bank Credit Facility Agreement), and (y) Cadista Pharmaceutical's current
assets. If Cadista Pharmaceutical's financial statements reflect negative EBITDA for any six (6) month period, it may be
required to fund a reserve account with ICICI Bank in an amount equal to six (6) months of interest payable on the principal amount
outstanding under the ICICI Bank Credit Facility Agreement for the prior six (6) month period.
The ICICI Bank Credit
Facility Agreement contains various covenants, including: covenants restricting changes in control (including that Jubilant
Life Sciences Limited maintain at least a 51% equity interest in us); upon ICICI Bank NY's request, requiring Cadista
Pharmaceuticals to obtain a credit rating with respect to itself or the loan transactions; covenants restricting the
repayment of affiliate indebtedness; and other restrictions similar to those contained in Cadista Pharmaceuticals'
credit agreement with State Bank of India, New York Branch ("SBNY"). All indebtedness of Cadista Pharmaceuticals
to us is subordinated to Cadista Pharmaceutical's obligations to ICICI Bank NY.
The ICICI Bank NY Credit Facility is secured by Cadista
Pharmaceutical's goods, inventory, accounts receivable, contract rights and current assets. ICICI Bank NY's security
interest ranks pari passu with the security interest of SBNY in the same assets.
The Amendment to the
Credit Agreement with SBNY
The amendment to
Cadista Pharmaceuticals' credit agreement with SBNY, in addition to effectuating modifications to reflect that
SBNY's security interest will rank pari passu in those items of collateral in which both ICICI Bank NY and SBNY will
have a security interest, effectuated the following changes: (i) the expiration date of the revolving credit facility was
extended from March 21, 2012 to November 18, 2012; (ii) a $1,000,000 sub-limit for the issuance of letters of credit was
established under the revolving credit facility; and (iii) requiring Cadista Pharmaceuticals to obtain a rating by a
reputable credit agency no later than September 30, 2012, failing which Cadista Pharmaceuticals will be required to pay
additional interest of 0.5% on the total commitment until it obtains such a rating.
Item 2.03        Creation
of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
The information in Item 1.01, which describes the material
terms of the ICICI Bank Credit Facility Agreement, and documents related to such agreement, is incorporated into this Item 2.03
by this reference.
Item 9.01 Financial Statements and Exhibits
Exhibit Number
Description
10.1
Credit Facility Agreement, dated, February 2, 2012, among Jubilant Cadista Pharmaceuticals, Inc. ("Cadista Pharmaceuticals"), and ICICI Bank Limited, New York Branch ("ICICI Bank NY")
10.2
Form of Promissory Note of Cadista Pharmaceuticals made to ICICI Bank NY, dated February 2, 2012
10.3
Security Agreement, dated February 2, 2012, between Cadista Pharmaceuticals and ICICI Bank NY
10.4
Subordination Agreement, dated February 2, 2012, between Cadista Holdings Inc. ("CHI") and ICICI Bank NY
10.5
Non-Disposal Undertaking, dated February 2, 2012, executed by CHI and Cadista Pharmaceuticals, for the benefit of ICICI Bank NY
10.6
Intercreditor Agreement, dated February 2, 2012, among ICICI Bank NY, State Bank of India, New York Branch, Cadista Pharmaceuticals, and CHI
10.7
Undertaking, dated February 2, 2012, by Jubilant Life Sciences Limited, for the benefit of ICICI Bank NY, acknowledged and agreed to by Cadista Pharmaceuticals and CHI
10.8
Second Amendment to Credit Modification Agreement, dated February 2, 2012, among State Bank of India, New York Branch ("SBNY"), Cadista Pharmaceuticals, and CHI
10.9
Amendment to Security Agreement, dated February 2, 2012, between SBNY and Cadista Pharmaceuticals
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
CADISTA HOLDINGS INC.
By:
/s/ Kamal Mandan
Kamal Mandan
Chief Financial Officer
Date:   February 7, 2012
EXHIBIT INDEX
Exhibit Number
Description
10.1
Credit Facility Agreement, dated, February 2, 2012, among Jubilant Cadista Pharmaceuticals, Inc. ("Cadista Pharmaceuticals"), and ICICI Bank Limited, New York Branch ("ICICI Bank NY")
10.2
Form of Promissory Note of Cadista Pharmaceuticals made to ICICI Bank NY, dated February 2, 2012
10.3
Security Agreement, dated February 2, 2012, between Cadista Pharmaceuticals and ICICI Bank NY
10.4
Subordination Agreement, dated February 2, 2012, between Cadista Holdings Inc. ("CHI") and ICICI Bank NY
10.5
Non-Disposal Undertaking, dated February 2, 2012, executed by CHI and Cadista Pharmaceuticals, for the benefit of ICICI Bank NY
10.6
Intercreditor Agreement, dated February 2, 2012, among ICICI Bank NY, State Bank of India, New York Branch, Cadista Pharmaceuticals, and CHI
10.7
Undertaking, dated February 2, 2012, by Jubilant Life Sciences Limited, for the benefit of ICICI Bank NY, acknowledged and agreed to by Cadista Pharmaceuticals and CHI
10.8
Second Amendment to Credit Modification Agreement, dated February 2, 2012, among State Bank of India, New York Branch ("SBNY"), Cadista Pharmaceuticals, and CHI.
10.9
Amendment to Security Agreement, dated February 2, 2012, between SBNY and Cadista Pharmaceuticals